市場調查報告書

糖尿病治療設備市場:成長率,趨勢及預測(2012年∼2024年)

Diabetes Care Devices Market - Growth, Trends, and Forecast (2012 - 2024)

出版商 Mordor Intelligence LLP 商品編碼 390762
出版日期 內容資訊 英文 110 Pages
商品交期: 2-3個工作天內
價格
糖尿病治療設備市場:成長率,趨勢及預測(2012年∼2024年) Diabetes Care Devices Market - Growth, Trends, and Forecast (2012 - 2024)
出版日期: 2019年02月01日內容資訊: 英文 110 Pages
簡介

全球糖尿病治療設備市場預計從2019年到2024年這段預測期間內,將以約6.8%的年複合成長率成長。

本報告提供全球糖尿病治療設備市場調查,整體市場趨勢,各監測設備、管理設備、地區的詳細趨勢,市場成長的影響要素分析,競爭情形,主要企業的簡介及佔有率等資訊總括性彙整。

目錄

第1章 簡介

  • 調查的成果
  • 調查的前提條件
  • 調查範圍

第2章 調查方法

第3章 摘要整理

第4章 市場動態

  • 市場概況
  • 市場成長要素
  • 市場阻礙因素
  • 波特的五力分析
    • 賣主談判力
    • 買方議價能力
    • 新加入廠商的威脅
    • 替代產品及服務的威脅
    • 競爭的激烈程度

第5章 市場區隔

  • 監測設備
    • 血中葡萄糖自我監視設備
    • 持續的血糖監測系統
  • 管理設備
    • 胰島素幫浦
    • 胰島素注射器
    • 胰島素濾芯
    • 拋棄式筆
    • 噴射注射器
  • 地區
    • 北美
    • 歐洲
    • 南美
    • 亞太地區
    • 中東、非洲

第6章 市場指標

  • 第一型糖尿病人口(2012年∼2012年)
  • 第二型糖尿病人口(2012年∼2012年)

第7章 競爭情形

  • 企業簡介
    • Abbott Diabetes Care
    • Roche
    • Johnson & Johnson
    • Dexcom
    • Medtronic
    • Arkray
    • Ascensia Diabetes Care
    • Agamatrix Inc.
    • Bionime Corporation
    • Acon
    • Medisana
    • Trivida
    • Rossmax
  • 企業佔有率分析
    • Roche
    • Johnson & Johnson
    • Abbott Diabetes Care
    • Dexcom
    • Medtronic
    • Novo Nordisk
    • Eli Lilly
    • Sanofi
    • 其他

第8章 市場機會及未來趨勢

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: 49436

Market Overview

The global diabetes care devices market is expected to register a CAGR of about 6.8% during the forecast period (2019 - 2023).

Asia-Pacific is anticipated to dominate the market during the forecast period, owing to rising prevalence of obesity in the region.

There has been a significant rise in insulin delivery systems technology, from insulin injections to insulin pumps.

Technological innovations and advances give much convenience in measuring the blood glucose levels. One such advancement in monitoring the blood glucose levels is established with continuous glucose monitoring devices.

Scope of the Report

The global diabetes care devices market is segmented by management devices (insulin pumps, insulin pens, syringes, cartridges, and jet injectors) and monitoring devices (self-monitoring blood glucose (hospital and personal use) and continuous glucose monitoring), and geography.

Key Market Trends - Rising Prevalence of Diabetes

As per a WHO report, the global prevalence of diabetes among adults of over 18 years accelerated from about 4.7%, in 1980, to over 8.5%, in 2014.

Diabetes prevalence has been rising rapidly in the middle- and low-income countries. In 2015, about 1.6 million deaths were directly associated with diabetes, which was around 2.2 million in 2012.

Almost half of all deaths attributable to high blood glucose occur before the age of 70 years. WHO projects that diabetes is likely to be the seventh-leading cause of death by 2030.

The growing prevalence of diabetes is the major driver for the global diabetes care devices market. Additionally, rising awareness regarding diabetes care, growing prevalence of obesity, and technological advancements are further driving the market for diabetes care devices.

North America to Dominate the Monitoring Devices Segment

The factors attributing to the North American market growth is the rising prevalence of diabetes, caused mainly due to urbanization and sedentary lifestyles.

Asia-Pacific is anticipated to grow tremendously during the forecast period, owing to factors, such as a high prevalence of diabetes, growing obese population, and government initiatives of raising awareness regarding diabetic care.

Competitive Landscape

There have been constant innovations driven by manufacturers to compete and struggle in the market. The major players, such as Abbott and Medtronic, resort to inorganic market strategies, such as mergers and acquisitions, to establish market dominance, while also adhering to organic growth strategies, which is evident from the R&D spending of these companies. Examples of few strategic outcomes include:

In March 2018, Medtronic PLC received the US Food and Drug Administration (FDA) approval for Guardian(TM) Connect continuous glucose monitoring (CGM) system, for diabetics aged between aged between 14-75 years.

In January 2018, Abbott announced that the FreeStyleLibre System, the company's revolutionary new continuous glucose monitoring (CGM) system, was available to Medicare patients in the United States.

Reasons to Purchase this report:

  • The market estimate (ME) sheet in Excel format
  • Report customization as per the client's requirements
  • 3 months of analyst support

Table of Contents

1 INTRODUCTION

  • 1.1 Study Deliverables
  • 1.2 Study Assumptions
  • 1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Drivers
  • 4.3 Restraints
  • 4.4 Porter's Five Forces Analysis
    • 4.4.1 Bargaining Power of Suppliers
    • 4.4.2 Bargaining Power of Consumers
    • 4.4.3 Threat of New Entrants
    • 4.4.4 Threat of Substitute Products and Services
    • 4.4.5 Intensity of Competitive Rivalry

5 Market Segmentation

  • 5.1 Monitoring Devices
    • 5.1.1 Self-Monitoring Blood Glucose Devices
      • 5.1.1.1 By Component (Value and Volume, 2012 - 2024)
      • 5.1.1.1.1 Glucometer Devices
      • 5.1.1.1.2 Test Strips
      • 5.1.1.1.3 Lancets
      • 5.1.1.2 By End User
      • 5.1.1.2.1 Hospital (Value and Volume, 2012 - 2024)
      • 5.1.1.2.1.1 Glucometer Devices
      • 5.1.1.2.1.2 Test Strips
      • 5.1.1.2.1.3 Lancets
      • 5.1.1.2.2 Personal (Value and Volume, 2012 - 2024)
      • 5.1.1.2.2.1 Glucometer Devices
      • 5.1.1.2.2.2 Test Strips
      • 5.1.1.2.2.3 Lancets
    • 5.1.2 Continuous Blood Glucose Monitoring
      • 5.1.2.1 By Component (Value and Volume, 2012 - 2024)
      • 5.1.2.1.1 Sensors
      • 5.1.2.1.2 Receivers
  • 5.2 Management Devices
    • 5.2.1 Insulin Pump
      • 5.2.1.1 Insulin Pump Device
      • 5.2.1.2 Insulin Pump Reservoir
      • 5.2.1.3 Infusion Set
    • 5.2.2 Insulin Syringes
    • 5.2.3 Insulin Cartridges
    • 5.2.4 Disposable Pens
    • 5.2.5 Jet Injectors
  • 5.3 Geography
    • 5.3.1 North America
      • 5.3.1.1 United States (Value and Volume, 2012 - 2024)
      • 5.3.1.1.1 By Monitoring Device (Self-Monitoring Blood Glucose, Continuous Glucose Monitoring)
      • 5.3.1.1.2 By Management Device (Insulin Pump, Syringes, Cartridges, Disposable Pens, Jet Injectors)
      • 5.3.1.1.3 By Company (Roche, Dexcom, Abbott, Novo Nordisk and Others)
      • 5.3.1.2 Canada (Value and Volume, 2012 - 2024)
      • 5.3.1.2.1 By Monitoring Device (Self-Monitoring Blood Glucose, Continuous Glucose Monitoring)
      • 5.3.1.2.2 By Management Device (Insulin Pump, Syringes, Cartridges, Disposable Pens, Jet Injectors)
      • 5.3.1.2.3 By Company (Roche, Dexcom, Abbott, Novo Nordisk and Others)
      • 5.3.1.3 Rest of North America (Value and Volume, 2012 - 2024)
      • 5.3.1.3.1 By Monitoring Device (Self-Monitoring Blood Glucose, Continuous Glucose Monitoring)
      • 5.3.1.3.2 By Management Device (Insulin Pump, Syringes, Cartridges, Disposable Pens, Jet Injectors)
      • 5.3.1.3.3 By Company (Roche, Dexcom, Abbott, Novo Nordisk and Others)
    • 5.3.2 Europe
      • 5.3.2.1 France (Value and Volume, 2012 - 2024)
      • 5.3.2.1.1 By Monitoring Device (Self-Monitoring Blood Glucose, Continuous Glucose Monitoring)
      • 5.3.2.1.2 By Management Device (Insulin Pump, Syringes, Cartridges, Disposable Pens, Jet Injectors)
      • 5.3.2.1.3 By Company (Roche, Dexcom, Abbott, Novo Nordisk and Others)
      • 5.3.2.2 Germany (Value and Volume, 2012 - 2024)
      • 5.3.2.2.1 By Monitoring Device (Self-Monitoring Blood Glucose, Continuous Glucose Monitoring)
      • 5.3.2.2.2 By Management Device (Insulin Pump, Syringes, Cartridges, Disposable Pens, Jet Injectors)
      • 5.3.2.2.3 By Company (Roche, Dexcom, Abbott, Novo Nordisk and Others)
      • 5.3.2.3 Italy (Value and Volume, 2012 - 2024)
      • 5.3.2.3.1 By Monitoring Device (Self-Monitoring Blood Glucose, Continuous Glucose Monitoring)
      • 5.3.2.3.2 By Management Device (Insulin Pump, Syringes, Cartridges, Disposable Pens, Jet Injectors)
      • 5.3.2.3.3 By Company (Roche, Dexcom, Abbott, Novo Nordisk and Others)
      • 5.3.2.4 Spain (Value and Volume, 2012 - 2024)
      • 5.3.2.4.1 By Monitoring Device (Self-Monitoring Blood Glucose, Continuous Glucose Monitoring)
      • 5.3.2.4.2 By Management Device (Insulin Pump, Syringes, Cartridges, Disposable Pens, Jet Injectors)
      • 5.3.2.4.3 By Company (Roche, Dexcom, Abbott, Novo Nordisk and Others)
      • 5.3.2.5 United Kingdom (Value and Volume, 2012 - 2024)
      • 5.3.2.5.1 By Monitoring Device (Self-Monitoring Blood Glucose, Continuous Glucose Monitoring)
      • 5.3.2.5.2 By Management Device (Insulin Pump, Syringes, Cartridges, Disposable Pens, Jet Injectors)
      • 5.3.2.5.3 By Company (Roche, Dexcom, Abbott, Novo Nordisk and Others)
      • 5.3.2.6 Russia (Value and Volume, 2012 - 2024)
      • 5.3.2.6.1 By Monitoring Device (Self-Monitoring Blood Glucose, Continuous Glucose Monitoring)
      • 5.3.2.6.2 By Management Device (Insulin Pump, Syringes, Cartridges, Disposable Pens, Jet Injectors)
      • 5.3.2.6.3 By Company (Roche, Dexcom, Abbott, Novo Nordisk and Others)
      • 5.3.2.7 Rest of Europe (Value and Volume, 2012 - 2024)
      • 5.3.2.7.1 By Monitoring Device (Self-Monitoring Blood Glucose, Continuous Glucose Monitoring)
      • 5.3.2.7.2 By Management Device (Insulin Pump, Syringes, Cartridges, Disposable Pens, Jet Injectors)
      • 5.3.2.7.3 By Company (Roche, Dexcom, Abbott, Novo Nordisk and Others)
    • 5.3.3 Latin America
      • 5.3.3.1 Mexico (Value and Volume, 2012 - 2024)
      • 5.3.3.1.1 By Monitoring Device (Self-Monitoring Blood Glucose, Continuous Glucose Monitoring)
      • 5.3.3.1.2 By Management Device (Insulin Pump, Syringes, Cartridges, Disposable Pens, Jet Injectors)
      • 5.3.3.1.3 By Company (Roche, Dexcom, Abbott, Novo Nordisk and Others)
      • 5.3.3.2 Brazil (Value and Volume, 2012 - 2024)
      • 5.3.3.2.1 By Monitoring Device (Self-Monitoring Blood Glucose, Continuous Glucose Monitoring)
      • 5.3.3.2.2 By Management Device (Insulin Pump, Syringes, Cartridges, Disposable Pens, Jet Injectors)
      • 5.3.3.2.3 By Company (Roche, Dexcom, Abbott, Novo Nordisk and Others)
      • 5.3.3.3 Rest of Latin America (Value and Volume, 2012 - 2024)
      • 5.3.3.3.1 By Monitoring Device (Self-Monitoring Blood Glucose, Continuous Glucose Monitoring)
      • 5.3.3.3.2 By Management Device (Insulin Pump, Syringes, Cartridges, Disposable Pens, Jet Injectors)
      • 5.3.3.3.3 By Company (Roche, Dexcom, Abbott, Novo Nordisk and Others)
    • 5.3.4 Asia-Pacific
      • 5.3.4.1 Japan (Value and Volume, 2012 - 2024)
      • 5.3.4.1.1 By Monitoring Device (Self-Monitoring Blood Glucose, Continuous Glucose Monitoring)
      • 5.3.4.1.2 By Management Device (Insulin Pump, Syringes, Cartridges, Disposable Pens, Jet Injectors)
      • 5.3.4.1.3 By Company (Roche, Dexcom, Abbott, Novo Nordisk and Others)
      • 5.3.4.2 South Korea (Value and Volume, 2012 - 2024)
      • 5.3.4.2.1 By Monitoring Device (Self-Monitoring Blood Glucose, Continuous Glucose Monitoring)
      • 5.3.4.2.2 By Management Device (Insulin Pump, Syringes, Cartridges, Disposable Pens, Jet Injectors)
      • 5.3.4.2.3 By Company (Roche, Dexcom, Abbott, Novo Nordisk and Others)
      • 5.3.4.3 China (Value and Volume, 2012 - 2024)
      • 5.3.4.3.1 By Monitoring Device (Self-Monitoring Blood Glucose, Continuous Glucose Monitoring)
      • 5.3.4.3.2 By Management Device (Insulin Pump, Syringes, Cartridges, Disposable Pens, Jet Injectors)
      • 5.3.4.3.3 By Company (Roche, Dexcom, Abbott, Novo Nordisk and Others)
      • 5.3.4.4 India (Value and Volume, 2012 - 2024)
      • 5.3.4.4.1 By Monitoring Device (Self-Monitoring Blood Glucose, Continuous Glucose Monitoring)
      • 5.3.4.4.2 By Management Device (Insulin Pump, Syringes, Cartridges, Disposable Pens, Jet Injectors)
      • 5.3.4.4.3 By Company (Roche, Dexcom, Abbott, Novo Nordisk and Others)
      • 5.3.4.5 Australia (Value and Volume, 2012 - 2024)
      • 5.3.4.5.1 By Monitoring Device (Self-Monitoring Blood Glucose, Continuous Glucose Monitoring)
      • 5.3.4.5.2 By Management Device (Insulin Pump, Syringes, Cartridges, Disposable Pens, Jet Injectors)
      • 5.3.4.5.3 By Company (Roche, Dexcom, Abbott, Novo Nordisk and Others)
      • 5.3.4.6 Vietnam (Value and Volume, 2012 - 2024)
      • 5.3.4.6.1 By Monitoring Device (Self-Monitoring Blood Glucose, Continuous Glucose Monitoring)
      • 5.3.4.6.2 By Management Device (Insulin Pump, Syringes, Cartridges, Disposable Pens, Jet Injectors)
      • 5.3.4.6.3 By Company (Roche, Dexcom, Abbott, Novo Nordisk and Others)
      • 5.3.4.7 Malaysia (Value and Volume, 2012 - 2024)
      • 5.3.4.7.1 By Monitoring Device (Self-Monitoring Blood Glucose, Continuous Glucose Monitoring)
      • 5.3.4.7.2 By Management Device (Insulin Pump, Syringes, Cartridges, Disposable Pens, Jet Injectors)
      • 5.3.4.7.3 By Company (Roche, Dexcom, Abbott, Novo Nordisk and Others)
      • 5.3.4.8 Indonesia (Value and Volume, 2012 - 2024)
      • 5.3.4.8.1 By Monitoring Device (Self-Monitoring Blood Glucose, Continuous Glucose Monitoring)
      • 5.3.4.8.2 By Management Device (Insulin Pump, Syringes, Cartridges, Disposable Pens, Jet Injectors)
      • 5.3.4.8.3 By Company (Roche, Dexcom, Abbott, Novo Nordisk and Others)
      • 5.3.4.9 Philippines (Value and Volume, 2012 - 2024)
      • 5.3.4.9.1 By Monitoring Device (Self-Monitoring Blood Glucose, Continuous Glucose Monitoring)
      • 5.3.4.9.2 By Management Device (Insulin Pump, Syringes, Cartridges, Disposable Pens, Jet Injectors)
      • 5.3.4.9.3 By Company (Roche, Dexcom, Abbott, Novo Nordisk and Others)
      • 5.3.4.10 Thailand (Value and Volume, 2012 - 2024)
      • 5.3.4.10.1 By Monitoring Device (Self-Monitoring Blood Glucose, Continuous Glucose Monitoring)
      • 5.3.4.10.2 By Management Device (Insulin Pump, Syringes, Cartridges, Disposable Pens, Jet Injectors)
      • 5.3.4.10.3 By Company (Roche, Dexcom, Abbott, Novo Nordisk and Others)
      • 5.3.4.11 Rest of Asia-Pacific (Value and Volume, 2012 - 2024)
      • 5.3.4.11.1 By Monitoring Device (Self-Monitoring Blood Glucose, Continuous Glucose Monitoring)
      • 5.3.4.11.2 By Management Device (Insulin Pump, Syringes, Cartridges, Disposable Pens, Jet Injectors)
      • 5.3.4.11.3 By Company (Roche, Dexcom, Abbott, Novo Nordisk and Others)
    • 5.3.5 Middle East & Africa
      • 5.3.5.1 Saudi Arabia (Value and Volume, 2012 - 2024)
      • 5.3.5.1.1 By Monitoring Device (Self-Monitoring Blood Glucose, Continuous Glucose Monitoring)
      • 5.3.5.1.2 By Management Device (Insulin Pump, Syringes, Cartridges, Disposable Pens, Jet Injectors)
      • 5.3.5.1.3 By Company (Roche, Dexcom, Abbott, Novo Nordisk and Others)
      • 5.3.5.2 Iran (Value and Volume, 2012 - 2024)
      • 5.3.5.2.1 By Monitoring Device (Self-Monitoring Blood Glucose, Continuous Glucose Monitoring)
      • 5.3.5.2.2 By Management Device (Insulin Pump, Syringes, Cartridges, Disposable Pens, Jet Injectors)
      • 5.3.5.2.3 By Company (Roche, Dexcom, Abbott, Novo Nordisk and Others)
      • 5.3.5.3 Egypt (Value and Volume, 2012 - 2024)
      • 5.3.5.3.1 By Monitoring Device (Self-Monitoring Blood Glucose, Continuous Glucose Monitoring)
      • 5.3.5.3.2 By Management Device (Insulin Pump, Syringes, Cartridges, Disposable Pens, Jet Injectors)
      • 5.3.5.3.3 By Company (Roche, Dexcom, Abbott, Novo Nordisk and Others)
      • 5.3.5.4 Oman (Value and Volume, 2012 - 2024)
      • 5.3.5.4.1 By Monitoring Device (Self-Monitoring Blood Glucose, Continuous Glucose Monitoring)
      • 5.3.5.4.2 By Management Device (Insulin Pump, Syringes, Cartridges, Disposable Pens, Jet Injectors)
      • 5.3.5.4.3 By Company (Roche, Dexcom, Abbott, Novo Nordisk and Others)
      • 5.3.5.5 South Africa (Value and Volume, 2012 - 2024)
      • 5.3.5.5.1 By Monitoring Device (Self-Monitoring Blood Glucose, Continuous Glucose Monitoring)
      • 5.3.5.5.2 By Management Device (Insulin Pump, Syringes, Cartridges, Disposable Pens, Jet Injectors)
      • 5.3.5.5.3 By Company (Roche, Dexcom, Abbott, Novo Nordisk and Others)
      • 5.3.5.6 Rest of Middle & Africa (Value and Volume, 2012 - 2024)
      • 5.3.5.6.1 By Monitoring Device (Self-Monitoring Blood Glucose, Continuous Glucose Monitoring)
      • 5.3.5.6.2 By Management Device (Insulin Pump, Syringes, Cartridges, Disposable Pens, Jet Injectors)
      • 5.3.5.6.3 By Company (Roche, Dexcom, Abbott, Novo Nordisk and Others)

6 MARKET INDICATORS

  • 6.1 Type 1 Diabetes Population (2012-2024)
  • 6.2 Type 2 Diabetes Population (2012-2024)

7 COMPETITIVE LANDSCAPE

  • 7.1 COMPANY PROFILES
    • 7.1.1 Abbott Diabetes Care
    • 7.1.2 Roche
    • 7.1.3 Johnson & Johnson
    • 7.1.4 Dexcom
    • 7.1.5 Medtronic
    • 7.1.6 Arkray
    • 7.1.7 Ascensia Diabetes Care
    • 7.1.8 Agamatrix Inc.
    • 7.1.9 Bionime Corporation
    • 7.1.10 Acon
    • 7.1.11 Medisana
    • 7.1.12 Trivida
    • 7.1.13 Rossmax
  • 7.2 COMPANY SHARE ANALYSIS
    • 7.2.1 Roche
    • 7.2.2 Johnson & Johnson
    • 7.2.3 Abbott Diabetes Care
    • 7.2.4 Dexcom
    • 7.2.5 Medtronic
    • 7.2.6 Novo Nordisk
    • 7.2.7 Eli Lilly
    • 7.2.8 Sanofi
    • 7.2.9 Others

8 MARKET OPPORTUNITIES AND FUTURE TRENDS